Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Category: pharmacogenomics

Evidence Matters in Genomic Medicine- Round 4: Where are we with Pharmacogenomic Tests?

Previously, CDC’s Office of Public Health Genomics announced a list of health-related genomic tests and applications, stratified into three tiers according to the availability of scientific evidence and evidence-based recommendations and systematic reviews. The list is intended to promote information exchange and dialogue among researchers, providers, policy makers, and the public. Initially the table relied Read More >

Posted on by W. David Dotson, Michael P. Douglas and Katherine Kolor, Office of Public Health Genomics, Centers for Disease Control and PreventionLeave a commentTags , , ,

Medications for the Masses? Pharmacogenomics is an Important Public Health Issue

Adverse drug events are a serious public health problem. Consider the following facts: an estimated 82% of American adults take at least one medication and 29% take five or more; 700,000 emergency department visits and 120,000 hospitalizations are due to adverse drug events annually; $3.5 billion is spent on extra medical costs of adverse drug Read More >

Posted on by Muin J Khoury, Director, Office of Public Health Genomics, Centers for Disease Control and Prevention3 CommentsTags , , ,